Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Filter Results:

Show Only Available Presentations

  • +

    ESMO Colloquium supported by Lilly Oncology in collaboration with MSD - How to best use immune checkpoint inhibitors in NSCLC: Single agents or combined with chemotherapy?

    • Type: ESMO Colloquium
    • Presentations: 7
    • Coordinates: 4/10/2019, 04:45 - 06:15, Room A
    • +

      Introduction

      11:45 - 11:50  |  Presenter: David Planchard

      • Abstract
      • Presentation

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Recommendation on second-line treatment according to first-line choice

      12:50 - 13:10  |  Presenter: David Planchard

      • Abstract
      • Presentation
      • Slides

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      Conclusion

      13:10 - 13:15  |  Presenter: David Planchard

      • Abstract

      No abstract available for this presentation

  • +

    NSCLC stage IV oncogenic addicted disease

    • Type: Educational session
    • Presentations: 6
    • Coordinates: 4/10/2019, 16:30 - 18:00, Room B
  • +

    Proffered Paper session I

    • Type: Proffered Paper session
    • Presentations: 8
    • Coordinates: 4/10/2019, 16:30 - 18:15, Room C
  • +

    Mini Oral session I

    • Type: Mini Oral session
    • Presentations: 8
    • Coordinates: 4/11/2019, 08:00 - 08:50, Room A
  • +

    Proffered Paper session II

    • Type: Proffered Paper session
    • Presentations: 8
    • Coordinates: 4/11/2019, 09:00 - 10:30, Room A
    • +

      110O - Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts)

      10:03 - 10:15  |  Presenter: Mihaela Aldea

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    Lunch & Poster Display session

    • Type: Poster Display session
    • Presentations: 170
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      23P - Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts)

      12:30 - 12:30  |  Presenter: Roberto Ferrara

      • Abstract

      Loading...

    • +

      183TiP - A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer

      12:30 - 12:30  |  Presenter: David Planchard

      • Abstract
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      185TiP - RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)

      12:30 - 12:30  |  Presenter: Luis Paz-Ares

      • Abstract
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    Mini Oral session II

    • Type: Mini Oral session
    • Presentations: 9
    • Coordinates: 4/11/2019, 16:40 - 17:40, Room C
    • +

      85O - Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC)

      16:45 - 16:50  |  Presenter: David Planchard

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    Should sequencing of ALK inhibitors be molecularly-guided?

    • Type: Controversy session
    • Presentations: 5
    • Coordinates: 4/12/2019, 17:45 - 18:45, Room A
  • +

    Do we treat patients with I-O until progression?

    • Type: Controversy session
    • Presentations: 5
    • Coordinates: 4/13/2019, 08:30 - 09:30, Room C